January 5, 2018 / 2:05 PM / Updated 11 minutes ago BRIEF-Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma Reuters Staff 1 Min Read 
Jan 5 (Reuters) - Retrophin Inc: 
* RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING 
* RETROPHIN SAYS IF CO EXERCISES OPTION TO BUY CENSA, COMPANY WILL HAVE TO PAY $65 MILLION IN UPFRONT CONSIDERATION 
* RETROPHIN - ‍AGREED TO FUND CERTAIN DEVELOPMENT ACTIVITIES OF CENSA‘S CNSA-001 PROGRAM IN AMOUNT EXPECTED TO BE ABOUT $16 MILLION THROUGH PROOF OF CONCEPT​ 
* RETROPHIN - ALSO ‍HAS RIGHT TO ACQUIRE CENSA ON TERMS AND SUBJECT TO CONDITIONS SET FORTH IN A SEPARATE AGREEMENT AND PLAN OF MERGER​ Source text: ( bit.ly/2EZP7YP ) Further company coverage: